Nektar Therapeutics

NASDAQ:NKTR

24.8 (USD) • At close July 3, 2025
Bedrijfsnaam Nektar Therapeutics
Symbool NKTR
Munteenheid USD
Prijs 24.76
Beurswaarde 307,194,844
Dividendpercentage 0%
52-weken bereik 6.45 - 37.38
Industrie Biotechnology
Sector Healthcare
CEO Mr. Howard W. Robin
Website https://www.nektar.com

An error occurred while fetching data.

Over Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder

Vergelijkbare Aandelen

Codexis, Inc. logo

Codexis, Inc.

CDXS

2.77 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

9.27 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

2.9 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

2.52 USD

Merus N.V. logo

Merus N.V.

MRUS

53.82 USD

Verve Therapeutics, Inc. logo

Verve Therapeutics, Inc.

VERV

11.28 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

6.69 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)